Behavioral Health

Cannabis use disorder: management and counseling

Clinical Overview and When to Suspect Cannabis Use Disorder

— ~3 in 10 regular users develop CUD; risk highest in adolescent-onset use, daily use, and high-potency products (concentrates, edibles, vape oils with THC >15–20%).

— Legalization has increased product potency and decreased perceived harm but has not reduced CUD prevalence.

— Comorbidities: anxiety, depression, PTSD, ADHD, other SUDs (especially tobacco, alcohol, opioids), and psychotic disorders.

— Adolescents/young adults with declining grades, work absenteeism, or new-onset amotivation

— Chronic cyclic vomiting with hot-shower relief (cannabinoid hyperemesis syndrome)

— New psychosis, panic attacks, or mood lability in a previously stable patient

— Pregnancy intake visits — universal screening recommended

— Pre-op evaluation, chronic pain on opioids, or unexplained tachycardia/conjunctival injection

— CUDIT-R (8 items, score ≥8 suggests hazardous use, ≥12 suggests likely CUD)

— Single-item NIDA Quick Screen ("In the past year, how often have you used marijuana?") integrates with SBIRT

— USPSTF (2020): screen all adults ≥18 for unhealthy drug use when services for accurate diagnosis, effective treatment, and appropriate care can be offered (Grade B)

— Differentiate use (not pathologic) from misuse (risky) from disorder (DSM criteria met)

— Functional impairment is the diagnostic anchor, not the quantity used or urine THC level

Board pearl: A positive urine cannabinoid screen alone does not establish CUD — diagnosis requires DSM-5-TR behavioral criteria. Conversely, a negative urine does not exclude CUD in someone using edibles intermittently.

Cannabis use disorder (CUD) is a DSM-5-TR diagnosis defined by a problematic pattern of cannabis use causing clinically significant impairment, with ≥2 of 11 criteria over 12 months (mild 2–3, moderate 4–5, severe ≥6).

Epidemiology and risk context:

When to suspect in ambulatory practice:

Screening tools:

Step 3 framing:

Presentation Patterns and Key History

— Impaired control: larger amounts/longer than intended, persistent desire/failed cutdown, time spent obtaining/using/recovering, craving

— Social impairment: failure of role obligations, continued use despite interpersonal problems, giving up activities

— Risky use: use in physically hazardous situations (driving), continued use despite knowledge of physical/psychological harm

— Pharmacologic: tolerance, withdrawal

— Sleep disturbance ("I can't sleep without it") — paradoxically a withdrawal driver

— Anxiety, irritability, decreased appetite within 1–3 days of cessation, peaking days 2–6, resolving by 1–2 weeks

— Cognitive complaints: poor concentration, memory lapses, slowed processing

— Chronic cough, wheeze, bronchitis in smoked/vaped users

— Recurrent ED visits for cyclic vomiting (CHS) in heavy chronic users

— Age of first use (earlier = higher CUD and psychosis risk)

— Route (joint, blunt, vape, dab, edible) and THC potency

— Frequency, quantity (grams/week, $/week), time of first use after waking

— Co-use: tobacco, alcohol, stimulants, opioids, benzodiazepines

— Driving under influence, occupational/legal consequences

— Prior quit attempts, longest abstinence, triggers for relapse

— Mental health: anxiety, depression, psychosis, trauma, suicidality

— Pregnancy intent, breastfeeding, custody concerns

— Family history of SUD or psychotic disorders

— Living situation (others using in home), employment requiring drug testing, safety-sensitive job (DOT, healthcare, aviation)

Step 3 management: Use a non-judgmental, motivational-interviewing stance — open questions, affirmations, reflections, summaries (OARS). Avoid confrontation; ambivalence is the norm and labeling a patient "addict" reduces engagement. Document specific functional impairments — these drive treatment intensity and justify referral.

Core DSM-5-TR symptom clusters (need ≥2 in 12 months):

Common presenting complaints:

High-yield history questions:

Family/social history:

Physical Exam Findings and Acute Intoxication Assessment

— Conjunctival injection (classic), dry mouth, increased appetite

— Tachycardia (often 100–140), mild BP variability (orthostatic hypotension possible)

— Slowed reaction time, impaired coordination, nystagmus uncommon

— Euphoria, time distortion, altered perception; at high doses → anxiety, paranoia, acute psychosis, depersonalization

— Edibles → delayed peak, frequent overdose presentations with profound sedation, vomiting, panic

— Triad: chronic heavy cannabis use, cyclic vomiting, compulsive hot bathing/showering for relief

— Exam: diffuse abdominal tenderness without peritonitis, often dehydrated, tachycardic

— Labs: AKI, hypokalemia, hypochloremic alkalosis from emesis

— Chronic bronchitis findings: wheezing, prolonged expiration, productive cough

— Dental disease, oral leukoplakia in heavy smokers

— Hyperalgesia or worsened chronic pain (paradoxical)

— Weight changes (gain from "munchies" or loss from CHS)

— Irritability, anxiety, sleep disturbance with vivid dreams, decreased appetite, restlessness, depressed mood, plus one physical sign: abdominal pain, tremor, sweating, fever, chills, headache

— HR >140 sustained, BP instability, altered mental status not improving, suspected co-ingestion (synthetic cannabinoids, stimulants)

Key distinction: Synthetic cannabinoids ("K2/Spice") cause far more severe presentations — seizures, AKI, severe agitation, psychosis, and even death — and often are not detected on standard urine THC immunoassay. Suspect when toxidrome is disproportionate to reported cannabis use.

Acute intoxication signs (onset minutes inhaled, 30–90 min oral; duration 2–6 h inhaled, up to 12 h edibles):

Cannabinoid hyperemesis syndrome (CHS):

Chronic use stigmata:

Withdrawal exam (DSM-5-TR cannabis withdrawal — onset 24–72 h, peak day 2–6):

Vital sign red flags requiring escalation:

Diagnostic Workup — Initial Labs and Screening

— Urine drug screen (UDS) immunoassay for THC-COOH: detects use, not impairment

— CBC, CMP — baseline, evaluate for AKI in CHS, electrolyte derangements

— TSH if mood/anxiety symptoms prominent

— Pregnancy test in patients capable of pregnancy

— HIV, HCV, syphilis screening if injection drug co-use or risk factors

— Lipid panel and HbA1c per USPSTF — competing risks often unaddressed

— CUDIT-R, ASSIST, or NIDA-modified ASSIST

— PHQ-9, GAD-7, PCL-5 (PTSD), AUDIT-C — high comorbidity yield

— Columbia Suicide Severity Rating Scale if depressive symptoms

— Chest pain, palpitations, syncope

— Cannabis increases acute MI risk ~5-fold in the hour after use; check for ischemia in older or cardiovascular-risk patients

— Look for sinus tachycardia, occasional ST changes

— CXR if chronic cough/hemoptysis to evaluate for bullae, infection, or EVALI (e-cigarette/vape associated lung injury) — bilateral ground-glass on CT

— Abdominal imaging only to exclude surgical abdomen in CHS

Board pearl: A positive UDS in a job applicant or pain-contract patient should prompt a conversation, not automatic dismissal — quantitative testing and clinical context distinguish single use from a disorder. Document the DSM criteria you used.

Diagnosis of CUD is clinical (DSM-5-TR) — no lab confirms the disorder. Testing supports safety, comorbidity assessment, and monitoring.

Initial laboratory considerations in outpatient evaluation:

Detection windows: single use 1–3 days; moderate use 7–10 days; chronic heavy daily use 30+ days (lipophilic storage)

False positives: efavirenz, pantoprazole (rare), dronabinol, hemp/CBD products

Confirmatory GC-MS or LC-MS/MS for medicolegal cases

Screening instruments to document:

ECG indications:

Imaging:

Diagnostic Workup — Advanced and Confirmatory Studies

— Quantitative urine THC-COOH/creatinine ratio: in monitored treatment, a rising ratio between visits indicates new use; a falling ratio suggests abstinence with continued release from fat stores. Useful in CCS-style longitudinal follow-up.

— Hair testing (90-day window) and oral fluid testing (<24–48 h, useful for recent use/driving) for workplace or custody cases

— Blood THC level: correlates poorly with impairment; many states use per se limits (e.g., 5 ng/mL) but pharmacokinetics make these unreliable in chronic users who remain positive while sober

— First-episode psychosis evaluation: MRI brain, EEG if atypical features, autoimmune encephalitis panel (NMDA-R antibodies) in subacute psychosis with neurologic signs — cannabis use does not exclude organic etiology

— Sleep study if persistent insomnia after 4+ weeks abstinence to evaluate OSA

— Pulmonary function tests in chronic smokers with dyspnea

— High-resolution CT chest if EVALI or bullous lung disease suspected

— Exclude alternatives: cyclic vomiting syndrome, gastroparesis (gastric emptying study), Addison's (cortisol), bowel obstruction (CT), intracranial process (CT head if neuro signs)

— Diagnosis confirmed by resolution with sustained cessation (≥1–2 weeks, sometimes longer)

— Stress testing if chest pain with use, particularly in age >40 or CV risk factors

— Echocardiogram if suspected cannabis-associated cardiomyopathy (rare, takotsubo-like)

— Formal neuropsych testing if cognitive deficits persist >4 weeks abstinent — distinguishes residual cannabis effect from primary cognitive disorder or ADHD

Key distinction: Cyclic vomiting syndrome and CHS look identical, but CHS requires heavy cannabis use AND resolves with cessation. Compulsive hot showers strongly favor CHS. Don't attribute recurrent vomiting to CHS until you've excluded surgical and endocrine causes on at least one workup.

Confirmatory and specialized testing scenarios:

Comorbidity workup when indicated:

CHS-specific workup:

Cardiovascular workup:

Psychometric and neurocognitive testing:

Risk Stratification and First-Line Management Logic

— Mild CUD (2–3 criteria): brief intervention + motivational interviewing in primary care, follow-up 2–4 weeks

— Moderate CUD (4–5 criteria): structured psychotherapy (CBT, MET, contingency management), consider group support, follow-up 1–2 weeks

— Severe CUD (≥6 criteria) or treatment failure: refer to specialty addiction medicine; consider intensive outpatient (IOP) or residential if functional collapse, co-occurring SUD, or failed outpatient

— Abstinence is optimal, especially with psychosis history, pregnancy, adolescence, or CHS

— Reduction/harm reduction acceptable for many adults: lower THC potency, eliminate driving under influence, avoid combustible products, separate cannabis from alcohol/opioids

— Motivational Enhancement Therapy (MET) — 2–4 sessions, builds intrinsic motivation

— Cognitive Behavioral Therapy (CBT) — identifies triggers, develops coping skills, 8–14 sessions

— Contingency Management (CM) — voucher/prize reinforcement for negative UDS; strongest evidence in cannabis trials

— Combined MET + CBT + CM outperforms any single modality

— Family-based therapies: Multidimensional Family Therapy (MDFT), Functional Family Therapy, Adolescent Community Reinforcement Approach (A-CRA)

— Confidentiality with caveats (safety, mandatory reporting) discussed upfront

— Treat depression, anxiety, ADHD, PTSD with evidence-based pharmacotherapy/psychotherapy

— Treat tobacco use disorder simultaneously — improves cannabis outcomes

Step 3 management: For a patient with moderate CUD and comorbid GAD, initiate SSRI for GAD, refer for CBT addressing both conditions, schedule 2-week follow-up, and document a specific quit date. Do not prescribe benzodiazepines for withdrawal anxiety — high abuse liability, no evidence of benefit.

Stratify by severity, function, and co-occurring conditions:

Treatment goals — collaboratively defined:

Evidence-based psychosocial first-line (no FDA-approved pharmacotherapy):

Adolescent first-line:

Address co-occurring conditions concurrently — sequential treatment fails:

Set quit date, anticipate withdrawal, plan supports

Pharmacotherapy — Off-Label and Adjunctive Agents

— N-acetylcysteine (NAC) 1200 mg PO BID — small RCTs show increased abstinence, especially in adolescents; well tolerated; GI side effects; cheap and OTC

— Gabapentin 300–600 mg TID — small trial showed reduced use and withdrawal symptoms; sedation, dizziness; caution in opioid co-use (respiratory depression risk)

— Topiramate — reduces quantity used but not abstinence; cognitive side effects often limit use

— Naltrexone 50 mg daily — modest reduction in cannabis use, particularly with co-occurring AUD; ensure 7-day opioid-free interval

— Sleep: mirtazapine 15 mg qhs or short-course non-benzodiazepine sleep hygiene; avoid Z-drugs and benzodiazepines

— Anxiety/irritability: hydroxyzine PRN, propranolol for somatic symptoms

— Nausea/appetite: ondansetron, small frequent meals; avoid dronabinol/nabilone for CUD (replaces the agonist)

— GI cramping: dicyclomine, hydration

— Benzodiazepines — addictive, no benefit, dangerous with co-use

— SSRIs — no benefit for CUD itself but treat comorbid depression/anxiety

— Bupropion — lowers seizure threshold; no efficacy data for CUD; reasonable for co-occurring tobacco use disorder

— Cannabinoid agonists (dronabinol, nabiximols) — investigational; not standard US care

— Acute: topical capsaicin cream to abdomen, haloperidol or droperidol, IV fluids; ondansetron often ineffective; benzodiazepines symptomatic only

— Definitive treatment: cessation

Board pearl: When the exam offers gabapentin, NAC, naltrexone, or bupropion for "cannabis use disorder pharmacotherapy," remember the stem-level truth: no FDA-approved drug exists, and the best answer is usually CBT/MET/contingency management. Drugs are adjuncts only.

No FDA-approved medication for CUD — all pharmacotherapy is off-label and adjunctive to psychosocial treatment. Discuss this explicitly during informed consent.

Agents with the best (modest) evidence:

Targeted symptomatic treatment of withdrawal (1–2 weeks):

Agents NOT recommended:

Special situation — CHS:

Behavioral Interventions — Depth and Delivery

— Ask about use, Advise to quit/reduce with personalized risk, Assess readiness, Assist with plan/referral, Arrange follow-up

— Even a single 5–15 minute session reduces use at 3–6 months

— Express empathy, develop discrepancy (between current use and patient's goals), roll with resistance, support self-efficacy

— Elicit "change talk" — DARN-C (Desire, Ability, Reasons, Need, Commitment)

— Functional analysis of use (antecedents → behavior → consequences)

— Trigger identification and avoidance/coping strategies

— Drug refusal skills, problem-solving training

— Lifestyle balance — activity scheduling to fill time previously spent using

— Relapse prevention: identifying high-risk situations, distinguishing lapse from full relapse

— Tangible reinforcement (vouchers, prizes) for verified abstinence (negative UDS)

— Escalating reinforcement schedule with reset after positive test

— Most effective during early treatment phase; effects attenuate after withdrawal of incentives — pair with skill-building therapies

— Marijuana Anonymous, SMART Recovery — adjunctive, free, widely available; recommend as supplement to formal treatment

— Validated apps and web programs (e.g., reSET) increase abstinence; useful for rural/underserved patients

— Reduces craving and relapse, particularly with co-occurring anxiety

— Behavioral couples therapy improves outcomes when partner is supportive

CCS pearl: In an outpatient CCS case for CUD, advance the clock as you order: (1) screen with CUDIT-R, (2) brief MI counseling, (3) referral to CBT/CM program, (4) treat comorbid depression/anxiety, (5) schedule follow-up in 2 weeks, (6) re-screen with UDS and PHQ-9 at follow-up. Order counseling, smoking cessation, and drug abuse counseling as discrete CCS orders.

Brief intervention in primary care (5 A's framework):

Motivational Interviewing (MI) core skills:

Cognitive Behavioral Therapy (CBT) components:

Contingency Management (CM):

Mutual-help groups:

Digital therapeutics:

Mindfulness-based relapse prevention (MBRP):

Family/couples therapy:

Special Populations — Older Adults and Renal/Hepatic Impairment

— Cannabis use in this group has risen sharply, often for chronic pain, insomnia, or chemotherapy-related symptoms

— Heightened risks: falls, syncope (orthostasis), delirium, drug interactions (warfarin INR elevation via CYP inhibition; sedation with opioids/benzodiazepines/sleep aids)

— Cardiovascular vulnerability: cannabis transiently raises HR and BP — increases MI and ischemic stroke risk; avoid in patients with recent ACS, unstable angina, severe HFrEF, or uncontrolled arrhythmia

— Cognitive impact compounds existing MCI/dementia; cannabis can precipitate or worsen confusion

— Ask specifically — many do not consider medical cannabis as "drug use"

— Review all routes including topicals (low systemic) versus edibles/inhaled

— Coordinate with state medical cannabis program if applicable; primary clinician is not required to certify but should know what the patient is taking

— THC and CBD undergo extensive hepatic metabolism via CYP3A4, CYP2C9, CYP2C19

— CBD inhibits CYP2C19 (increases clobazam, warfarin) and CYP3A4

— In cirrhosis, increased free drug, prolonged effects, higher risk of encephalopathy; counsel against use

— Metabolites renally excreted; in advanced CKD, accumulation may prolong effects but no dose adjustment guidance exists

— CHS in dialysis patients can cause dangerous electrolyte shifts

— Warfarin: CBD/THC increase INR — monitor closely after initiation/cessation

— Clobazam, valproate, tacrolimus, everolimus, certain SSRIs: increased levels with CBD

— CNS depressants: additive sedation

— Sympathomimetics: additive tachycardia

Step 3 management: For a 72-year-old on warfarin starting medical cannabis for chemotherapy nausea, increase INR monitoring weekly for 4 weeks, anticipate warfarin dose reduction, and counsel on fall precautions. Consider alternatives such as olanzapine-based antiemetic regimens.

Older adults (≥65):

Screening and counseling in older adults:

Hepatic impairment:

Renal impairment:

Drug interactions to flag:

Special Populations — Pregnancy, Breastfeeding, and Adolescents

— ACOG: counsel all pregnant patients to discontinue cannabis in pregnancy and while trying to conceive. No safe level established.

— Universal screening at first prenatal visit (verbal screen + consider UDS with consent and disclosure of consequences)

— Risks: low birth weight, small for gestational age, preterm birth, NICU admission; emerging data on neurodevelopmental and executive function effects, attention problems in offspring

— Cannabis crosses placenta; THC concentrates in fetal tissues

— Hyperemesis gravidarum patients increasingly self-medicate with cannabis — redirect to doxylamine-pyridoxine, ondansetron, metoclopramide

— THC is lipophilic and concentrates in breast milk; detectable up to 6 days

— AAP and ACOG advise against cannabis use during lactation; however, breastfeeding is generally still encouraged over formula in most cases — individualized risk-benefit discussion

— Brain development continues to age ~25; adolescent cannabis use is associated with lower IQ trajectory, worse executive function, higher psychosis risk (especially with high-potency products and genetic vulnerability — AKT1, COMT)

— Use CRAFFT 2.1 screen (Car, Relax, Alone, Forget, Family/Friends, Trouble)

— Confidentiality with explicit limits (suicide, abuse, homicidal ideation, mandatory reporting per state law) — discuss before screening

— First-line: family-based therapy (MDFT, A-CRA) + CM; medication only for comorbid conditions

— Cannabis worsens psychotic symptoms, increases hospitalization, reduces antipsychotic efficacy

— Strongly counsel cessation; integrate addiction and psychiatric care

Board pearl: A pregnant patient using cannabis for nausea should be redirected to doxylamine 10 mg + pyridoxine 10 mg PO as first-line, with ondansetron reserved for refractory cases. Document the counseling — failure to counsel about cannabis in pregnancy is a recurrent Step 3 stem.

Pregnancy:

Breastfeeding:

Adolescents:

Patients with serious mental illness:

Complications and Adverse Outcomes

— Cannabis-induced psychosis — acute, transient; up to 50% progress to schizophrenia spectrum within years, especially with high-potency or daily use and genetic risk

— Worsening of underlying schizophrenia, bipolar disorder, anxiety, depression

— Suicidality — independent association with suicidal ideation and attempts, particularly in adolescents

— Amotivational syndrome — apathy, blunted goal-directed behavior; resolves variably with abstinence

— Acute: impaired attention, working memory, executive function, psychomotor speed

— Chronic heavy use: residual deficits up to 4 weeks abstinent; adolescent use may produce persistent decline

— Acute MI risk ~5x in the hour after use

— Increased ischemic stroke, atrial fibrillation, peripheral arteritis (cannabis arteritis — Buerger-like)

— Reversible cardiomyopathy, takotsubo

— Chronic bronchitis, large airway inflammation; no clear COPD or lung cancer link from cannabis alone, though combustion products are carcinogenic

— EVALI (more associated with vitamin E acetate in vaping products) — bilateral infiltrates, hypoxemia

— Pneumothorax, bullous lung disease in heavy inhalation users

— CHS — recurrent vomiting, dehydration, AKI, electrolyte derangement, esophagitis, Mallory-Weiss tears

— Motor vehicle crashes — doubled risk; combined with alcohol, multiplicative

— Pediatric edible ingestions — surging ED visits, sometimes requiring ICU

— Gateway debate aside, CUD increases risk of tobacco, alcohol, and other SUD development

— Job loss, academic decline, custody loss, legal consequences (DUI, possession)

Key distinction: EVALI vs cannabis-induced bronchitis: EVALI presents acutely with bilateral ground-glass opacities, hypoxemia, fever and is linked to vaping THC products containing vitamin E acetate. Treat with steroids and supportive care; report to public health.

Psychiatric:

Cognitive:

Cardiovascular:

Pulmonary:

GI:

Injury:

Substance use:

Social/occupational:

When to Escalate Care — Inpatient, ICU, and Specialty Referral

— Acute psychosis with agitation, danger to self/others — chemical restraint with second-generation antipsychotic (olanzapine 5–10 mg, haloperidol 5 mg ± lorazepam 2 mg if no respiratory concern)

— Suicidal ideation with plan/intent — psychiatric admission

— Severe CHS with dehydration, AKI, electrolyte derangement — admit for IV fluids, electrolyte repletion, haloperidol/droperidol, capsaicin

— Chest pain in temporal relation to cannabis use — rule out ACS per standard protocols (troponin, ECG, observation)

— Suspected synthetic cannabinoid toxicity — seizures, AKI, rhabdomyolysis, severe agitation → ICU

— Pediatric edible ingestion with lethargy or respiratory depression — admit for observation, supportive care

— Status epilepticus, respiratory failure, hemodynamic instability, severe rhabdomyolysis, malignant hyperthermia-like presentations (synthetics)

— Severe CUD (≥6 criteria) failing primary care management

— Co-occurring SUD, severe psychiatric comorbidity, or pregnancy with active use

— Adolescents — family-based addiction specialty

— Refractory CHS despite documented abstinence (reconsider diagnosis)

— Level 1: outpatient (<9 h/week)

— Level 2.1: intensive outpatient (IOP, 9–19 h/week)

— Level 2.5: partial hospitalization

— Level 3: residential

— Level 4: medically managed inpatient

— Warm handoff to addiction specialist or behavioral health better than passive referral

— Confirm appointment within 7–14 days

CCS pearl: In a patient with acute cannabis-induced psychosis, do NOT discharge from the ED without psychiatric evaluation. Order suicide risk assessment, urine drug screen including synthetic cannabinoids, basic metabolic panel, CK, ECG, and psychiatry consultation. Reassess clock-forward.

Emergency department / urgent escalation:

ICU criteria:

Specialty referral indications:

Levels of care (ASAM criteria):

Coordination of care:

Key Differentials — Other Substance Use Disorders

— Alcohol use disorder (AUD): shared sedation, social impairment; distinguish with AUDIT-C, GGT, MCV elevation, blood alcohol; withdrawal differs sharply (tremor, autonomic hyperactivity, seizures, DTs vs cannabis irritability/sleep)

— Tobacco use disorder: nearly half of cannabis smokers also smoke tobacco; address both simultaneously — combined cessation improves cannabis outcomes

— Stimulant use disorder (cocaine, methamphetamine): tachycardia and psychosis overlap; UDS, mydriasis, hypertension, hyperthermia, longer psychosis duration favor stimulants

— Opioid use disorder: pinpoint pupils, sedation, respiratory depression; constipation chronic; offer naloxone and MOUD (buprenorphine, methadone, naltrexone)

— Sedative-hypnotic use disorder: benzodiazepine/Z-drug use — dangerous withdrawal (seizures), often used to manage cannabis withdrawal insomnia

— Hallucinogen use disorder: HPPD (hallucinogen persisting perception disorder) can mimic chronic cannabis perceptual changes

— Inhalant use disorder: distinct olfactory, neurologic findings; teens

— Synthetic cannabinoid use disorder ("K2/Spice"): severe, atypical, undetectable on standard UDS — high index of suspicion

— Common; treat the most dangerous SUD first (opioids, alcohol, benzodiazepines for withdrawal severity), then layer cannabis treatment

— Do not delay cannabis-directed counseling waiting for "primary" substance resolution

Key distinction: Cannabis withdrawal is uncomfortable but not dangerous (no seizures, no death). Alcohol and benzodiazepine withdrawal can be fatal. If a patient is using both, prioritize medically supervised detox for the alcohol/benzo component first.

Differentials within the substance-use category (frequently co-occurring):

Polysubstance use:

Behavioral addictions (gambling, gaming, internet) — frequent comorbidity in adolescents

Key Differentials — Non-Substance Conditions That Mimic CUD

— Primary psychotic disorders (schizophrenia, schizoaffective, brief psychotic disorder): if psychosis persists >1 month after sustained abstinence, reclassify diagnosis

— Bipolar disorder: mood lability, impulsivity, substance use during mania; obtain longitudinal mood history

— Major depressive disorder / persistent depressive disorder: amotivation, anhedonia, sleep disturbance — overlap with chronic cannabis effects

— Generalized anxiety / panic disorder / PTSD: many patients self-medicate; treat the underlying disorder with SSRI/SNRI + trauma-focused therapy

— ADHD: poor focus, impulsivity drive self-medication; consider non-stimulant first (atomoxetine, bupropion) in CUD, then carefully chosen stimulant if needed with monitoring

— Thyroid disease: hyperthyroidism mimics intoxication (tachycardia, anxiety); hypothyroidism mimics amotivation

— Neurocognitive disorders: especially in older adults — formal testing after sustained abstinence

— Sleep disorders (OSA, narcolepsy): masked by cannabis-induced sleep alterations

— Cyclic vomiting syndrome (idiopathic) — identical presentation but no cannabis association; does not improve with cessation

— Gastroparesis — gastric emptying study

— Acute intermittent porphyria — episodic abdominal pain, neuropsychiatric features

— Adrenal insufficiency — fatigue, nausea, hypotension, hyperpigmentation

— Increased intracranial pressure — vomiting with headache, papilledema

— Pheochromocytoma — episodic tachycardia, HTN, sweating, anxiety

— Anxiety disorder with cardiac sensitization — sinus tach mistaken for intoxication

Board pearl: When a stem mentions psychosis "persisting after 1 month of documented abstinence," the diagnosis is no longer cannabis-induced psychotic disorder — reclassify as schizophrenia spectrum and treat with long-term antipsychotic therapy + integrated addiction care.

Conditions that present with overlapping psychiatric, cognitive, or physical features:

Mimics of cannabis-related physical complications:

Secondary Prevention and Long-Term Plan

— Identify high-risk situations (stress, social cues, specific people/places, insomnia, anniversaries)

— Coping strategies: urge surfing, distraction, opposite action, calling support

— Relapse vs lapse framing — a single use is not failure; re-engage immediately

— Maintain contact with therapist, support group, sponsor

— Treat insomnia (CBT-I, sleep hygiene, melatonin, low-dose doxepin/trazodone if needed)

— Treat pain non-cannabinoid: PT, mindfulness, duloxetine, topical agents, judicious opioids only when appropriate

— Manage anxiety/depression with SSRIs + therapy

— Exercise (≥150 min/week moderate-intensity) — reduces craving and improves mood

— Sleep regularization

— Nutrition counseling, particularly after CHS-related weight loss

— Social engagement, vocational support

— Frequent early (weekly/biweekly × 4–8 weeks), then monthly × 6 months, then quarterly

— Each visit: assess use (timeline followback), withdrawal, function, comorbidities, medication adherence, screen PHQ-9/GAD-7

— Family therapy where appropriate, supportive others trained in non-enabling responses

— If polysubstance use including opioids — prescribe naloxone, fentanyl test strips per state law

— For continued users: counsel against driving for ≥6–8 h after inhaled use and ≥12 h after edibles; avoid combustion (use vaporizer with regulated product); avoid co-use with alcohol/sedatives; use lower-potency products

Step 3 management: At each follow-up, document: (1) days of use in past 30, (2) PHQ-9/GAD-7, (3) functional status (work, relationships), (4) adherence to therapy, (5) updated relapse prevention plan, (6) flu/COVID/HPV/pneumococcal/Tdap vaccines and cancer screening — preventive care often neglected in SUD patients.

Relapse prevention plan — co-create and document:

Address modifiable triggers:

Lifestyle prescriptions:

Continuing care visits:

Family/social system engagement:

Naloxone and harm reduction:

Follow-Up, Monitoring, and Counseling Cadence

— Initial brief intervention → follow-up at 1–2 weeks

— Engagement in therapy → weekly for first month, then every 2–4 weeks for 3 months

— Stable abstinence/reduced use → monthly × 6 months, then every 3 months for ≥1 year

— Annual review thereafter; CUD is a chronic relapsing condition

— Self-reported use (timeline followback past 7–30 days)

— Validated scales: CUDIT-R, PHQ-9, GAD-7, severity of dependence scale

— UDS — discuss purpose (clinical, not punitive); quantitative THC-COOH/creatinine ratio for trend in chronic users

— Functional metrics: school/work attendance, relationships, finances, legal

— Vital signs (BP, HR, weight), sleep quality

— Affirm progress, explore ambivalence, reinforce change talk

— Anticipate triggers (holidays, exams, stressors)

— Update plan for high-risk situations

— Driving: no driving within 6–8 h of inhalation, 12 h of edibles; no combined use with alcohol (synergistic impairment)

— Workplace: drug testing implications, safety-sensitive positions

— Reproductive: fertility effects (decreased sperm count, anovulation); pregnancy/lactation avoidance

— Mental health: cannabis-psychosis link, especially with high-THC products

— Cardiovascular: increased MI/stroke risk acutely after use

— Children in the home: secure storage of edibles to prevent pediatric ingestion

— HPV, hepatitis A/B, Tdap, influenza, COVID-19, pneumococcal per age

— Cancer screening (cervical, colorectal, breast, lung) per USPSTF

— STI screening if risk factors

CCS pearl: When the case advances 2 weeks after starting CBT for CUD, re-screen with CUDIT-R and PHQ-9, order UDS quantitative, document functional change, and adjust plan. Don't forget to order counseling/family and counseling/exercise as discrete advance orders.

Recommended monitoring schedule:

Monitoring parameters:

Counseling priorities at every visit (motivational interviewing):

Specific counseling content:

Vaccinations and preventive care often missed:

Ethical, Legal, and Patient Safety Considerations

— Federal protections for SUD treatment records exceed standard HIPAA — written, specific consent required to disclose to employers, schools, family

— Recent revisions (2024) ease some sharing with general health records, but consent principles remain

— State laws vary on minors' right to consent to SUD treatment; most allow some level

— Discuss limits of confidentiality upfront: suicidal/homicidal intent, abuse, situations endangering minor — these must be disclosed

— Suspected child abuse/neglect triggered when caregiver use endangers child — varies by state; cannabis use alone is generally not sufficient, but driving with child intoxicated, neglect, or unsafe storage of edibles may qualify

— Pregnancy: some states mandate reporting of substance use during pregnancy — know your state law; counsel patient before testing

— Counsel about state per se limits and zero tolerance for commercial drivers

— Some states require physician reporting of impaired drivers (e.g., recurrent DUIs with continued use) — know local statute

— Physician judgment whether to certify is personal; no federal approval; conflicts with controlled-substance prescribing for opioids/benzos (many state PDMPs flag cannabis certification)

— Discuss risks/alternatives, document thoroughly, avoid certification for adolescents and pregnant patients

— Cannabis remains federally Schedule I despite state legalization; federal employees, DOT-regulated workers (commercial drivers, pilots, transit), and military have zero tolerance

— NAC, gabapentin, naltrexone are off-label for CUD — document discussion of evidence and alternatives

— Discharge from inpatient psych/addiction without scheduled outpatient follow-up within 7 days is a major relapse and overdose risk; ensure warm handoff and confirmed appointment

— Black and Hispanic patients are disproportionately arrested for cannabis despite similar use rates; trauma-informed, non-judgmental care reduces disparities

Board pearl: A pregnant patient who screens positive for cannabis should be counseled, not reported, unless your state mandates otherwise. Document counseling, plan, and follow-up — punitive responses reduce prenatal care engagement and worsen outcomes.

Confidentiality and 42 CFR Part 2:

Adolescent confidentiality:

Mandatory reporting:

Driving and DUI:

Medical cannabis certification:

Employment and federal law:

Informed consent for off-label pharmacotherapy:

Transition-of-care safety:

Stigma and equity:

High-Yield Associations and Rapid-Fire Facts

Key distinction: Hazardous use (CUDIT-R 8–11) gets brief intervention in primary care; likely CUD (≥12) warrants structured therapy and possibly specialty referral.

No FDA-approved pharmacotherapy for CUD — psychosocial treatment is first-line.

CBT + MET + Contingency Management = strongest evidence base.

Cannabis withdrawal peaks day 2–6, resolves by ~2 weeks; symptoms: irritability, anxiety, insomnia, vivid dreams, decreased appetite, restlessness.

CHS triad: heavy chronic use + cyclic vomiting + compulsive hot showers. Treatment: cessation; acute care with topical capsaicin and haloperidol.

MI risk ~5x in the hour after cannabis use; increased stroke and arrhythmia risk.

USPSTF (2020) recommends screening adults ≥18 for unhealthy drug use (Grade B).

CUDIT-R ≥8 suggests hazardous use; ≥12 likely CUD.

Adolescent screening: CRAFFT 2.1.

Pregnancy: ACOG recommends cessation; redirect HG to doxylamine-pyridoxine first.

Breastfeeding: THC concentrates in milk; advise against use but generally continue breastfeeding.

Synthetic cannabinoids not detected on standard UDS — severe toxicity (seizures, AKI, psychosis).

CBD inhibits CYP2C19 — increases warfarin, clobazam, tacrolimus.

Adolescent cannabis use → increased risk of schizophrenia spectrum (especially with high-potency THC, family history, AKT1/COMT variants).

Cannabis-induced psychotic disorder: if persists >1 month after sustained abstinence, reclassify as primary psychotic disorder.

42 CFR Part 2 protects SUD records beyond HIPAA — written consent required for most disclosures.

Federally Schedule I — federal/DOT/military employees: zero tolerance.

First-line meds with modest evidence (off-label): NAC (esp. adolescents), gabapentin, naltrexone.

Avoid for CUD: benzodiazepines, dronabinol (replaces agonist), bupropion (no efficacy for CUD).

Sleep: avoid Z-drugs/benzos; mirtazapine, trazodone, CBT-I preferred.

Driving: 6–8 h after inhalation, 12 h after edibles; never combine with alcohol.

5 A's (Ask, Advise, Assess, Assist, Arrange) and OARS (Open questions, Affirm, Reflect, Summarize) frame brief intervention.

Detection windows: single use 1–3 d; chronic heavy use 30+ d.

Board Question Stem Patterns

Step 3 management: When in doubt on a Step 3 stem, the answer pattern is usually (1) motivational interviewing/brief intervention, (2) refer to CBT/CM, (3) treat comorbidity, (4) follow up in 1–2 weeks — not a pill.

Stem 1 — Adolescent decline: 16-year-old with falling grades, irritability, social withdrawal; mother reports finding a vape pen. UDS positive THC. → Answer: Family-based therapy (MDFT/A-CRA) and motivational interviewing; address confidentiality with limits; do not start pharmacotherapy first-line.

Stem 2 — CHS: 24-year-old daily cannabis user with recurrent vomiting, relieved by hot showers; CT abdomen unremarkable. → Acute: topical capsaicin + haloperidol + IV fluids; definitive: cessation. Ondansetron often ineffective.

Stem 3 — Pregnancy: 26-year-old at 9 weeks gestation using cannabis for nausea. → Counsel cessation, prescribe doxylamine-pyridoxine as first-line, schedule close follow-up; do not report unless mandated.

Stem 4 — Withdrawal management: 30-year-old quit cannabis 3 days ago, irritable, can't sleep. → Non-pharm sleep hygiene, mirtazapine or trazodone if needed; CBT; avoid benzodiazepines.

Stem 5 — Acute psychosis: 19-year-old with new paranoid psychosis after dabbing high-potency THC. → ED management with olanzapine, observation, urine for synthetics, psychiatric follow-up; if persists >1 month abstinent → reclassify.

Stem 6 — Older adult with warfarin: 70-year-old starts medical cannabis; INR rises. → CBD-warfarin interaction; reduce warfarin dose, monitor weekly.

Stem 7 — Pediatric edible ingestion: 4-year-old found lethargic after eating "candy"; UDS positive THC. → Supportive care, observation, child protective consultation if neglect; counsel secure storage.

Stem 8 — Pharmacotherapy question: "Which medication is FDA-approved for CUD?" → None; best answer typically psychosocial therapy or off-label NAC.

Stem 9 — Synthetic cannabinoid: severe agitation, seizures, AKI; negative standard UDS. → Suspect synthetic cannabinoid (K2/Spice); supportive care, ICU.

Stem 10 — Confidentiality: employer requests SUD records. → Refuse without specific written consent (42 CFR Part 2).

Stem 11 — Driving counseling: long-haul truck driver uses cannabis weekends. → DOT zero tolerance; counsel cessation, document, advise re: career implications.

One-Line Recap

Cannabis use disorder is a chronic, relapsing DSM-5-TR clinical diagnosis best managed with motivational interviewing, CBT, contingency management, and treatment of comorbid psychiatric conditions — there is no FDA-approved pharmacotherapy, and counseling on safety, pregnancy, driving, and high-potency products is as important as any prescription.

Board pearl: Step 3's favorite CUD answer is rarely a drug — it is brief intervention, targeted therapy referral, comorbidity treatment, and a follow-up visit on the calendar.

Diagnosis is clinical, not laboratory — DSM-5-TR criteria over 12 months; UDS confirms exposure, not impairment or disorder; severity (mild/moderate/severe) guides level of care.

First-line treatment is psychosocial: motivational interviewing + CBT + contingency management; off-label adjuncts (NAC, gabapentin, naltrexone) have modest evidence; avoid benzodiazepines for withdrawal; treat comorbid depression, anxiety, ADHD, and tobacco use concurrently.

Special populations require tailored counseling: ACOG recommends cessation in pregnancy with doxylamine-pyridoxine for nausea; adolescents need family-based therapy and CRAFFT screening; older adults face fall, drug interaction (warfarin, clobazam via CBD-CYP inhibition), and cardiovascular risks.

Recognize the high-yield complications and red flags: cannabinoid hyperemesis syndrome (heavy use + cyclic vomiting + hot showers → cessation + topical capsaicin), acute MI risk within 1 hour of use, cannabis-induced psychosis (reclassify if >1 month abstinent), synthetic cannabinoids ("K2/Spice") undetected on standard UDS, and pediatric edible ingestions — and always integrate safety counseling on driving, secure edible storage, and avoiding combined use with alcohol alongside follow-up at 1–2 weeks with CUDIT-R, PHQ-9, and GAD-7 tracking.